Tirosint Cost in New Hampshire 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does It Cost More Than Standard Levothyroxine?

Tirosint is a branded formulation of levothyroxine T4 manufactured by IBSA Pharma. It comes in two presentations: a soft gelatin capsule (Tirosint) approved by the FDA in 2013, and a liquid unit-dose ampule called Tirosint-SOL approved in 2020. Both eliminate most of the excipients found in standard levothyroxine tablets, which matters clinically for patients with absorption disorders, autoimmune gut conditions, or documented sensitivity to acacia, lactose, or dyes in generic tablets.

Generic levothyroxine tablets cost $4, $12 per month at most NH pharmacies with a GoodRx coupon. The price gap between that and $230/month for Tirosint is not arbitrary. Gelatin capsule and liquid manufacturing requires tighter stability controls, smaller batch sizes, and cold-chain handling for the liquid form, all of which press the cost upward.

A 2014 study by Vita et al. published in Endocrine (N=31, patients with Hashimoto's thyroiditis and persistent TSH elevation on tablets) showed that switching to levothyroxine soft gel capsules produced statistically significant TSH normalization at 6 months compared to continued tablet therapy, with P<0.001 [1]. The FDA-approved label for Tirosint confirms the indication for hypothyroidism and pituitary TSH suppression, and notes that bioavailability differences between formulations require individualized dose titration if patients switch [2].

The American Thyroid Association guidelines state that "the goal of therapy is to restore the patient to a euthyroid state with a TSH value in the target range for that patient's clinical situation," meaning any approved formulation that achieves that target is clinically acceptable [3]. Tirosint becomes a medically justified upgrade specifically when standard tablets fail to normalize TSH despite adequate dosing.

Tirosint Cash Price in New Hampshire in 2026

The retail cash price at New Hampshire pharmacies sits at approximately $230 per month for a 30-day supply of Tirosint gel capsules in 2026. That figure holds across CVS, Walgreens, and Walmart locations in Manchester, Nashua, Concord, and Portsmouth based on publicly listed pharmacy pricing data.

Prices vary by capsule strength. Lower mcg strengths (13 mcg, 25 mcg) may run slightly cheaper per unit, while mid-range strengths (75 mcg, 100 mcg) are most commonly prescribed and priced at the $225, $235 range. Tirosint-SOL liquid ampules carry a comparable or marginally higher list price due to the cold-chain packaging.

GoodRx and RxSaver discount cards apply to many retail pharmacies in NH. Using a GoodRx coupon at a participating NH pharmacy can bring the cash price for Tirosint gel caps to approximately $180, $210/month depending on the specific strength and zip code, though savings vary and cards cannot be combined with insurance benefits at the point of sale. The FDA advises patients to confirm whether discount cards affect their insurance deductible tracking before using them [4].

Costco pharmacy locations in NH (Salem and Nashua) occasionally carry lower cash prices for branded thyroid medications. Patients without insurance who take Tirosint long-term should call each pharmacy directly, since Costco's non-member pharmacy pricing is publicly accessible under NH state pharmacy transparency rules.

Does New Hampshire Medicaid Cover Tirosint?

NH Medicaid (administered through NH DHHS and managed care partners including WellSense Health Plan and Granite State Health Plan) does not cover Tirosint as a preferred drug on the 2026 NH Medicaid preferred drug list. Generic levothyroxine tablets are covered at the lowest tier with minimal or zero copay for eligible beneficiaries.

A prior authorization request for Tirosint through NH Medicaid requires documentation of a clinical reason standard tablets are inadequate. Specifically, documented malabsorption, achlorhydria, persistent TSH dysregulation despite dose optimization on tablets, or allergy to tablet excipients are the categories most likely to support a PA. Even with a PA, approval is not guaranteed, and NH Medicaid reserves the right to require step therapy through at least one alternative branded or authorized-generic formulation first.

Research published in JAMA Internal Medicine (2014) examining levothyroxine bioavailability found that co-administration of coffee, calcium, or proton pump inhibitors reduces tablet absorption by 25 to 40%, which can contribute to TSH instability that a gel cap formulation may correct [5]. This type of peer-reviewed documentation strengthens a PA rationale, but NH DHHS clinical reviewers weigh cost-effectiveness heavily when formulary exceptions are evaluated.

Patients on NH Medicaid who cannot access Tirosint through the formulary process should discuss 503A compounded levothyroxine gel caps with their prescriber as an alternative route, described in the section below.

Which Private Insurance Plans Cover Tirosint in New Hampshire?

Coverage depends heavily on the specific plan, not just the insurer name. Anthem Blue Cross Blue Shield NH, Harvard Pilgrim Health Care NH, Ambetter NH, and Cigna plans sold on the NH ACA marketplace each maintain their own formularies, and Tirosint tier placement shifts annually.

As of 2026, most commercial plans in NH place Tirosint on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A Tier 3 copay in NH commercial plans typically runs $45, $90 per 30-day fill after deductible. Tier 4 placement means $90, $150 or more per fill, and some high-deductible health plans (HDHPs) require patients to pay the full cash price until the deductible is met.

Anthem BCBS NH members can check real-time formulary status through the Anthem Drug Cost Estimator. Harvard Pilgrim NH members use the plan's Find-a-Drug tool. Neither tool guarantees final cost without running a live claim. The IBSA savings card (covered in a later section) can offset cost for commercially insured patients on virtually any plan that does not prohibit manufacturer copay assistance.

Plans that exclude manufacturer copay assistance (common in some employer self-insured plans and ACA APTC-subsidized plans) may render the IBSA card unusable. Patients should call the member services number on the back of their insurance card and ask specifically whether their plan participates in copay assistance programs before counting on the savings card at the pharmacy counter.

The Endocrine Society's 2022 clinical practice guideline on thyroid hormone therapy notes that "branded levothyroxine preparations may be preferred in patients with documented absorption disorders or excipient intolerances," which provides a published clinical rationale for insurance appeal letters when coverage is initially denied [6].

Is Compounded Levothyroxine Gel Cap Legal in New Hampshire?

Yes. New Hampshire permits compounded levothyroxine in liquid or gel capsule form through state-licensed 503A compounding pharmacies operating under NH Board of Pharmacy rules and federal FDCA Section 503A. This is not a gray area in NH law as of 2026.

A 503A pharmacy must prepare compounded levothyroxine on a patient-specific prescription from a licensed NH prescriber. The pharmacy cannot make large batches in advance for general sale, which distinguishes 503A from 503B outsourcing facilities. Quality standards under 503A require United States Pharmacopeia (USP) Chapter 795 and 797 compliance for non-sterile and sterile preparations respectively, though levothyroxine gel caps are non-sterile and fall under USP 795 [7].

Cost through a 503A pharmacy in NH ranges from approximately $0 (when covered under specific compounding benefit plans) to $40/month cash, representing a substantial reduction from the $230 Tirosint list price. Patients with no insurance, patients on NH Medicaid who cannot get a Tirosint PA approved, or patients whose insurance excludes branded medications entirely may find this route the most accessible.

The clinical tradeoff is that compounded levothyroxine lacks FDA review of the finished product's potency and bioequivalence. A cross-sectional survey cited in Thyroid (2019) found potency variability in compounded thyroid preparations of plus or minus 15% from label claim in some samples, which can affect TSH stability in patients requiring tight thyroid control, such as thyroid cancer survivors on suppression therapy [8]. Patients and prescribers should weigh this variability against cost and access barriers. Monitoring TSH every 6 to 8 weeks after starting compounded levothyroxine is advisable until stability is confirmed.

The HealthRX NH Tirosint Access Decision Framework below helps prescribers choose the most appropriate route for each patient based on insurance status, Medicaid eligibility, and documented clinical need:

Step 1. Confirm clinical indication for gel cap over tablet (achlorhydria, malabsorption, documented TSH instability on tablets, excipient intolerance). Step 2. Check current NH formulary status for patient's specific plan using live pharmacy benefit check. Step 3. If commercially insured and Tirosint is on formulary at Tier 3 or 4, apply IBSA savings card. Step 4. If savings card is prohibited or plan is NH Medicaid, initiate prior authorization with PubMed-cited clinical documentation. Step 5. If PA is denied or cost remains above patient threshold, refer to NH-licensed 503A pharmacy for compounded levothyroxine gel cap with 6-week TSH follow-up built into the care plan.

How the IBSA Savings Card Works in New Hampshire

IBSA Pharma offers a copay savings program for commercially insured patients prescribed Tirosint or Tirosint-SOL. The program is not limited to NH and does not require state-level enrollment, but patients must meet eligibility criteria.

Eligible patients must have commercial insurance (not Medicaid, not Medicare Part D, not CHIP, not any federal or state government health program). They must be residents of the United States. The savings card can bring the patient's copay to as low as $0 per month for patients whose plan covers Tirosint, with a typical maximum annual benefit of $2,500, $3,600 per year depending on the program terms active in 2026.

To activate the card, patients visit the IBSA Tirosint savings card portal (ibsa.us or via the prescription label insert), complete a brief eligibility form, and receive a card number or electronic card to present at an NH pharmacy. The pharmacist enters the BIN/PCN/group numbers alongside the patient's insurance information, and the savings card pays the difference between the insurance cost-share and the program cap.

The card does not work at pharmacies that are not enrolled in the program. All major NH chain pharmacies (CVS, Walgreens, Rite Aid, Walmart) participate. Independent NH pharmacies should be confirmed individually before the patient attempts to fill.

If a patient's plan is classified as an ACA marketplace plan receiving an advanced premium tax credit (APTC), the savings card may still be usable depending on plan structure, but some plans categorize APTC-subsidized enrollees differently for copay card eligibility. Patients in this situation should call the IBSA savings program line before their first fill.

Can I Get Tirosint via Telehealth in New Hampshire?

Telehealth prescribing of Tirosint is legal in New Hampshire in 2026 for patients with an established hypothyroidism diagnosis or documented clinical indication. NH RSA 329:1-d permits prescribing through synchronous audio-visual telehealth encounters. Prescribers must hold an active NH medical license or a valid multistate compact licensure (NH joined the Interstate Medical Licensure Compact).

A telehealth provider can legally prescribe Tirosint after conducting an appropriate clinical evaluation, reviewing prior TSH and Free T4 lab results, and documenting the medical rationale for using a gel cap or liquid formulation rather than a standard tablet. A physical examination is not required for thyroid medication management under NH telehealth rules in most cases, though prescribers must use clinical judgment regarding when in-person assessment is necessary.

Labs for TSH monitoring can be ordered to any NH CLIA-certified draw site. LabCorp and Quest Diagnostics both operate patient service centers in Manchester, Concord, Nashua, Derry, and Portsmouth. TSH plus Free T4 is the standard monitoring panel; the American Association of Clinical Endocrinologists recommends rechecking TSH 4 to 8 weeks after any dose change or formulation switch [9].

Telehealth platforms serving NH patients must comply with NH prescribing regulations and the federal Ryan Haight Online Pharmacy Consumer Protection Act for controlled substances. Levothyroxine is not a controlled substance, so the Ryan Haight prescribing restrictions do not apply, making telehealth Tirosint prescribing straightforwardly legal without requiring prior in-person visits under current NH law.

What Is the Cheapest Way to Get Tirosint in New Hampshire?

The least-expensive route depends on insurance status. For uninsured or underinsured patients, 503A compounded levothyroxine gel caps at $0, $40/month represent the lowest direct cost, assuming a qualified NH prescriber and a licensed NH compounding pharmacy are involved. For commercially insured patients whose plan covers Tirosint, the IBSA savings card combined with Tier 3 insurance coverage can reduce the effective cost to $0/month within annual program limits.

For NH Medicaid patients who cannot obtain PA approval, compounded levothyroxine is again the most viable low-cost route. For patients on Medicare Part D, the savings card is not usable, and Tirosint coverage through Part D plans varies. Patients on Medicare should use the Medicare Plan Finder tool (medicare.gov) to compare specific Part D formularies and identify plans that cover Tirosint at the lowest tier available to them for 2026 enrollment.

A 2021 analysis published in Thyroid examining adherence and outcomes in patients on branded vs. generic levothyroxine found that patients who experienced repeated formulation switches due to insurance changes had higher rates of TSH instability, reinforcing the clinical value of maintaining a consistent formulation once TSH is stabilized [10]. This evidence supports the case for pursuing a stable branded or compounded formulation through whatever access pathway is most sustainable long-term for a given NH patient.

Monitoring TSH After Starting Tirosint in New Hampshire

TSH normalization after starting or switching to Tirosint typically occurs within 6 to 12 weeks. The full pharmacodynamic effect of a levothyroxine dose change on TSH takes 4 to 6 weeks due to the long half-life of T4 (approximately 7 days) and the time required for pituitary TSH secretion to re-equilibrate [11].

The standard NH clinical practice following a formulation switch is to recheck TSH at 6 to 8 weeks. If TSH is within the patient's individual target range, the dose is confirmed. If not, dose adjustment follows and TSH is rechecked another 6 to 8 weeks later. Most patients stabilize within two titration cycles.

Patients switching from standard tablets to Tirosint may not need a dose change, but should not assume dose equivalence without lab confirmation. Vita et al. (2014) noted that some patients required a modest dose reduction when switching from tablets to gel caps, likely because of improved bioavailability in the gel cap formulation [1]. This means TSH could fall below range in a small percentage of patients, particularly those who were previously undertreated on tablets due to absorption issues.

The FDA label for Tirosint recommends dose titration based on TSH and clinical response, not a fixed conversion ratio from tablet dose [2]. Prescribers should document the pre-switch TSH value and target TSH range in the chart to make follow-up interpretation straightforward.

Tirosint Dosing Reference for New Hampshire Prescribers

Tirosint gel capsules are available in strengths of 13, 25, 50, 75, 88, 100, 112, 125, 137, and 150 mcg. Tirosint-SOL is available as a 20 mcg/mL oral liquid in unit-dose ampules. The gel cap is the more commonly prescribed form in NH outpatient practice.

Standard adult replacement dosing for primary hypothyroidism begins at 1.6 mcg/kg/day. Older adults (age 65 and above) or patients with cardiovascular disease typically start at 12.5 to 25 mcg/day with gradual titration upward [12]. Thyroid cancer patients on TSH-suppression therapy are dosed to a lower TSH target, often below 0.1 mIU/L, per American Thyroid Association differentiated thyroid cancer guidelines [13].

Tirosint should be taken 30 to 60 minutes before the first meal of the day, separated from calcium supplements, iron supplements, antacids, cholestyramine, and proton pump inhibitors by at least 4 hours, since these agents all reduce levothyroxine absorption [2]. The gel cap formulation partially mitigates coffee interactions compared to tablets, as demonstrated in a small crossover trial published in Thyroid (2013) showing that coffee reduced levothyroxine absorption from tablets by 36% but had no statistically significant effect on gel cap absorption (P<0.05 for the between-formulation difference) [14].

Pregnant patients with hypothyroidism typically require a 25 to 30% dose increase starting in the first trimester. The Endocrine Society's 2012 clinical practice guideline on thyroid and pregnancy recommends monitoring TSH every 4 weeks through mid-pregnancy and at 30 weeks gestation in women on levothyroxine [15]. NH prescribers managing pregnant patients on Tirosint should coordinate with obstetric providers to ensure TSH targets remain in the trimester-specific reference range.